GLP-1 and Heart Health: The SELECT Trial Explained

For years, GLP-1 medications were viewed primarily as treatments for type 2 diabetes, with weight loss as a welcome side effect. Then came the SELECT trial—a landmark study that fundamentally changed how doctors think about these drugs. SELECT demonstrated that semaglutide (the active ingredient in Wegovy and Ozempic) reduces major cardiovascular events in people with obesity or overweight who do not have diabetes.

This finding has been called a "practice-changing" moment in cardiology. It suggests that GLP-1 medications are not just metabolic drugs but genuine cardiovascular medicines. This article explains what SELECT found, why it matters, and how it is reshaping treatment for millions of patients.

Part 1: What Was the SELECT Trial?

SELECT stands for Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity Without Diabetes . It was a multicenter, double-blind, randomized, placebo-controlled trial—the gold standard of clinical research.

The Basics

• Number of participants: 17,604 patients across 804 sites in 41 countries

• Population: Adults aged 45 years or older with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 kg/m² or higher, but without diabetes

• Intervention: Once-weekly subcutaneous semaglutide at a dose of 2.4 mg (the Wegovy dose) vs. placebo, added to standard of care

• Duration: Mean treatment duration of 34 months; mean follow-up of nearly 40 months

The Primary Outcome

The main question SELECT sought to answer was simple: does semaglutide reduce major adverse cardiovascular events (MACE) —a composite of cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke?

Part 2: The Results—A 20% Reduction in Cardiovascular Events

The results were striking and statistically robust.

• Semaglutide group: 569 out of 8,803 patients (6.5%) experienced a primary outcome event

• Placebo group: 701 out of 8,801 patients (8.0%) experienced a primary outcome event

This translates to a 20% reduction in MACE with semaglutide compared to placebo (hazard ratio [HR] = 0.80; 95% confidence interval: 0.72–0.90; p < 0.001) .

Secondary Outcomes

The benefits extended beyond the primary composite endpoint:

In other words, patients taking semaglutide were less likely to die from any cause, less likely to be hospitalized for heart failure, and far less likely to develop diabetes during the trial period.

Part 3: What About Weight Loss? (A Surprising Finding)

Semaglutide is famous for producing substantial weight loss. In SELECT, patients on the drug lost an average of 10.2% of their body weight, compared to just 1.5% in the placebo group. Waist circumference decreased by 7.7 cm vs. 1.3 cm, and waist-to-height ratio improved by 6.9% vs. 1.0% .

Given these numbers, it would be natural to assume that the cardiovascular benefits came from the weight loss. But a prespecified analysis of SELECT data, published in The Lancet in late 2025, revealed something more interesting .

The Benefit Was Not Driven by Weight Loss Alone

Researchers analyzed whether the magnitude of Glp 1 for weight loss in the first 20 weeks predicted subsequent cardiovascular benefit. It did not. Patients who lost less weight still experienced significant MACE reduction .

Furthermore, when researchers statistically adjusted for changes in waist circumference (a measure of central/visceral fat), they found that waist reduction explained only 33% of the observed cardiovascular benefit .

As the study authors concluded: "The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit beyond adiposity reduction" .

This finding has profound implications. It suggests that semaglutide is not simply helping hearts by helping people lose weight—it is doing something directly beneficial to the cardiovascular system.

Part 4: How Does Semaglutide Protect the Heart? (Proposed Mechanisms)

If weight loss does not fully explain the benefit, what does? Research points to several "pleiotropic" (multifaceted) effects of GLP-1 receptor agonists that go beyond metabolism .

1. Anti-Inflammatory Effects

Chronic low-grade inflammation is a key driver of atherosclerosis (plaque buildup in arteries). GLP-1 agonists have been shown to reduce inflammatory markers like high-sensitivity C-reactive protein (hs-CRP) by 20-30% in human studies . They also inhibit the NLRP3 inflammasome, a molecular complex that triggers inflammatory responses .

2. Improved Endothelial Function

The endothelium—the lining of blood vessels—plays a critical role in cardiovascular health. GLP-1 agonists enhance the function of this lining by increasing nitric oxide (NO) availability, which helps blood vessels dilate properly. Studies have shown that exenatide improves flow-mediated dilation (a measure of endothelial health) by 2-3% .

3. Direct Anti-Atherosclerotic Actions

Research suggests GLP-1 agonists may stabilize existing arterial plaques, making them less likely to rupture and cause heart attacks or strokes. They also inhibit vascular smooth muscle cell proliferation and migration—processes that contribute to plaque growth .

4. Blood Pressure and Lipid Improvements

GLP-1 agonists consistently lower systolic blood pressure by 2-5 mmHg and improve lipid profiles, including reductions in LDL cholesterol and triglycerides .

Together, these mechanisms create a comprehensive cardiovascular protective effect that operates alongside—and independent of—weight loss.

Part 5: Beyond SELECT—What Else Do We Know?

SELECT is not the only trial exploring GLP-1s and heart health. A growing body of evidence supports their cardiovascular benefits across different populations.

Heart Failure with Preserved Ejection Fraction (HFpEF)

A systematic review and meta-analysis published in 2025, combining data from five randomized controlled trials (including the STEP-HFpEF trial), found that GLP-1 receptor agonists reduced the composite outcome of all-cause mortality and heart failure hospitalization by 27% in patients with HFpEF (HR 0.73; 95% CI: 0.60-0.90) . The effect on heart failure hospitalizations alone was even more pronounced, with a 43% reduction (HR 0.57) .

Hospitalization Reduction

A prespecified exploratory analysis of SELECT data, published in JAMA Cardiology, examined the impact of semaglutide on hospital admissions. The results were striking: semaglutide was associated with a 10% reduction in total hospitalizations for any indication (18.3 vs. 20.4 admissions per 100 patient-years) and a similar reduction in days spent in the hospital .

This finding extends the benefits of semaglutide beyond cardiovascular prevention to reducing the overall burden of illness requiring hospitalization .

Liver Health Benefits

Another prespecified analysis of SELECT data, published in Nature Medicine, found that semaglutide reduced MACE even in patients at substantial risk for liver fibrosis, with the greatest benefit seen in those at highest risk (HR 0.66 for MACE) . Semaglutide also improved liver enzyme levels regardless of whether patients had metabolic dysfunction-associated steatotic liver disease (MASLD) .

Part 6: Clinical Implications—How SELECT Changed Practice

A New Indication

Following SELECT, regulatory bodies around the world expanded the indication for semaglutide 2.4 mg (Wegovy) to include cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity, regardless of whether they have diabetes.

This means that a patient who has had a heart attack and has a BMI of 27 or higher may now be prescribed Wegovy specifically to prevent another cardiovascular event—even if they have no interest in weight loss.

Beyond BMI Thresholds

The SELECT findings also suggest that prescribing restrictions based strictly on BMI may be too narrow. The cardiovascular benefits were consistent across all baseline weight and waist circumference categories, from BMI <30 kg/m² to BMI ≥40 kg/m² .

As one commentary noted, GLP-1 receptor agonists should be "reconceptualised as disease-modifying treatments rather than solely medications for glycaemic control or weight loss" .

What About Other GLP-1s and Dual Agonists?

SELECT focused specifically on semaglutide 2.4 mg. However, other GLP-1 receptor agonists (liraglutide, dulaglutide) have also shown cardiovascular benefits in patients with diabetes . The dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound) has shown promising cardiovascular effects as well, though dedicated outcome trials are still ongoing .

Part 7: Safety and Tolerability in SELECT

No discussion of a clinical trial is complete without addressing side effects. In SELECT, adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group vs. 8.2% of the placebo group .

The majority of these discontinuations were due to gastrointestinal side effects—nausea, vomiting, diarrhea, and constipation—which are well-known effects of GLP-1 agonists due to their impact on gastric emptying . These effects are typically most pronounced during dose escalation and often improve over time.

For the 83.4% of patients who remained on treatment, the cardiovascular benefits substantially outweighed the risks.

The Bottom Line

The SELECT trial was a watershed moment in cardiovascular medicine. It demonstrated that semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight or obesity—even in the absence of diabetes .

Crucially, this benefit is not fully explained by weight loss. Semaglutide appears to have direct cardiovascular effects, including anti-inflammatory actions, improved endothelial function, and plaque stabilization, that protect the heart and blood vessels through multiple pathways .

For patients, the message is clear: if you have heart disease and a BMI of 27 or higher, a GLP-1 medication like semaglutide may offer significant cardiovascular protection, regardless of whether you need to lose weight or have diabetes.

For clinicians, SELECT has expanded the role of GLP-1 agonists from metabolic therapies to bona fide cardiovascular drugs—a transformation that will likely shape treatment guidelines for years to come.